BREAKING: The FDA has authorized booster doses of the Pfizer-BioNTech and Moderna COVID-19 vaccines for everyone 18 and older who is already considered fully vaccinated.
The U.S. Food and Drug Administration on Friday authorized booster doses of the Pfizer-BioNTech and Moderna COVID-19 vaccines for everyone 18 and older who is already considered fully vaccinated, teeing up many Americans to gain extra protection ahead of a possible winter surge in cases.
Currently, only those 65 and older and people who are at high-risk of contracting the virus, either because of their job, where they live, or underlying conditions, are eligible for Pfizer-BioNTech and Moderna boosters six months after their second shot. Everyone 18 and older who received Johnson & Johnson's one-dose COVID-19 vaccine is eligible for a booster two months after getting their initial shot.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
FDA Could Authorize Moderna Booster Shots for All Adults This WeekThe FDA could authorize booster shots of Moderna’s COVID-19 vaccine for all adults as early as this week.
Lire la suite »
FDA to Authorize Pfizer Booster Shots for All Adults This WeekThe FDA intends to authorize booster shots of the Pfizer-BioNTech COVID-19 vaccine for all adults this week — potentially as early as Thursday.
Lire la suite »
BMO initiates Pfizer at outperform, says Covid drugs and strong pipeline will boost pharma stockNew for subscribers: BMO initiates Pfizer at outperform, says Covid drugs and strong pipeline will boost pharma stock. Check out CNBCPro today.
Lire la suite »
Plaintiffs' lawyers get $115 mln in fees in Pfizer EpiPen dealA federal judge on Wednesday signed off on Pfizer Inc's $345 million settlement resolving claims by consumers who say they overpaid for the emergency allergy treatment EpiPen, and awarded plaintiffs' firms including Robbins Geller Rudman & Dowd and Keller Rohrback $115 million in fees.
Lire la suite »